ATARA BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $9.20 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-16
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-03-31 was $14.07.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $9.20, a 85.95% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $65.50, a 1013.95% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.88, a 44.11% decline from fiscal 2021.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $10.52, a 32.16% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $9.20 10-K · filed 2026-03-16 | ||||
| 2023-12-31 | $65.50 10-K · filed 2025-03-07 | $2.62 10-K · filed 2024-03-28 | |||
| 2022-12-31 | $5.88 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | $10.52 10-K · filed 2023-02-08 | ||||
| 2020-12-31 | $7.96 10-K · filed 2023-02-08 | ||||
| 2019-12-31 | $18.06 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $22.96 10-K · filed 2021-03-01 | ||||
| 2015-09-30 | $19.22 10-Q · filed 2015-11-06 | ||||
| 2015-06-30 | $15.32 10-Q · filed 2015-08-07 | ||||
| 2015-03-31 | $14.07 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | $7.37 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |